Day One Biopharmaceuticals, Inc.
DAWN
$9.73
$0.748.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.80M | 33.91M | 30.76M | 29.21M | 93.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.80M | 33.91M | 30.76M | 29.21M | 93.76M |
| Cost of Revenue | 4.48M | 3.77M | 2.88M | 2.98M | 1.59M |
| Gross Profit | 35.32M | 30.14M | 27.88M | 26.23M | 92.17M |
| SG&A Expenses | 28.15M | 28.97M | 29.33M | 29.74M | 28.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.05M | 68.88M | 71.83M | 94.54M | 64.13M |
| Operating Income | -24.25M | -34.97M | -41.07M | -65.33M | 29.64M |
| Income Before Tax | -19.73M | -30.32M | -36.00M | -59.24M | 36.16M |
| Income Tax Expenses | -- | -- | -- | 6.47M | -882.00K |
| Earnings from Continuing Operations | -19.73M | -30.32M | -36.00M | -65.71M | 37.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.73M | -30.32M | -36.00M | -65.71M | 37.04M |
| EBIT | -24.25M | -34.97M | -41.07M | -65.33M | 29.64M |
| EBITDA | -23.37M | -34.09M | -40.25M | -64.71M | 30.24M |
| EPS Basic | -0.19 | -0.29 | -0.35 | -0.64 | 0.38 |
| Normalized Basic EPS | -0.12 | -0.18 | -0.22 | -0.36 | 0.23 |
| EPS Diluted | -0.19 | -0.29 | -0.35 | -0.64 | 0.38 |
| Normalized Diluted EPS | -0.12 | -0.18 | -0.22 | -0.36 | 0.23 |
| Average Basic Shares Outstanding | 103.38M | 103.07M | 102.71M | 102.44M | 96.62M |
| Average Diluted Shares Outstanding | 103.38M | 103.07M | 102.71M | 102.44M | 96.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |